Clinical Trial Update: Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 neoadjuvant trial is evaluating Endostar with Docetaxel and Epirubicin for breast cancer; the current trial status is not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ELLENCE (Epirubicin hydrochloride)
• Endostar (recombinant human endostatin)
• Taxotere (docetaxel)

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer | Phase 3 | Status: UNKNOWN